Apollomics

Apollomics ROCE

The Return on Capital Employed (ROCE) of Apollomics (APLM) as of Oct 16, 2026 is 297.15 %. In the previous year, Return on Capital Employed (ROCE) was -866.28 % — a change of -134.30% (higher).

ROCE

297.15 %

YoY

-134.30%

Last updated:

In 2025, Apollomics's return on capital employed (ROCE) was 297.15 %, a -134.30% increase from the -866.28 % ROCE in the previous year.

The Apollomics ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2019
40.76 USD
Jan 1, 2020
31.77 USD
Jan 1, 2021
23.89 USD
Jan 1, 2022
10.06 USD
Jan 1, 2023
-130.99 USD
Jan 1, 2024
-866.28 USD
Jan 1, 2025
297.15 USD
The Apollomics ROCE history
YEARROCEYoY
297.15 %-134.30%
-866.28 %+561.33%
-130.99 %-1,402.10%
10.06 %-57.89%
23.89 %-24.80%
31.77 %-22.05%
40.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Apollomics Stock analysis

What does Apollomics do? Apollomics Inc is a clinical-stage biotechnology company based in Foster City, California, operating within the Health Care sector. The company went public via an IPO on November 26, 2021, and is listed under the ticker APLM with ISIN KYG0411D1236. Apollomics focuses on the discovery and development of oncology therapies designed to address unmet medical needs. The company's pipeline includes approximately nine drug candidates, six of which are in clinical development. Its lead program involves vebreltinib (APL-101), a c-Met inhibitor being evaluated in a Phase II multicohort clinical trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. Another key candidate is uproleselan (APL-106), an E-Selectin antagonist under development as an adjunct to standard chemotherapy for acute myeloid leukemia and other hematologic cancers. Apollomics aims to create therapies that can be combined with existing treatments to enhance immune system engagement and target specific molecular pathways in cancer. The company's website is www.apollomicsinc.com. Apollomics is engaged in advancing innovative oncology treatments through clinical research and development. Apollomics is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Apollomics's Return on Capital Employed (ROCE)

Apollomics's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Apollomics's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Apollomics's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Apollomics’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Apollomics stock

Return on Capital Employed (ROCE) of Apollomics is 297.15 % in 2025.

Return on Capital Employed (ROCE) of Apollomics changed from -866.28 % to 297.15 %, representing a -134.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Apollomics since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Apollomics with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Apollomics

All Key Metrics — Apollomics